CBLI stock: buy or sell?
May 26th, 2020
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation.
Should I buy CBLI stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Cleveland BioLabs stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Cleveland BioLabs stock a buy?
Financial institutions and banks post stock ratings everyday.Unfortunately, we couldn't find any rating for CBLI stock for the last 30 days.
CBLI stock analysis
Cleveland BioLabs shares stepped up 1.49% to $2.05 today.
Cleveland BioLabs shares stepped up 1.49% to $2.05 today. Since SMA100d and SMA200d crossed up on March, CBLI price slid a -34.92%. Since price and SMA200d lines crossed up on January, CBLI climbed $0.96 (88.07%).
Shares of Cleveland BioLabs stepped up a good 1.49% this week. By mid May CBLI climbed an exceptional 24.06% in just one week. Late April CBLI plunged a spooky -5.66% in just one week.
In a weekly time frame, Cleveland BioLabs stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, CBLI might consolidate in a flat-base, waiting to break out over or down under . Since SMA20w and SMA40w crossed up early March, CBLI price slid a -38.62%. Since price and SMA40w lines crossed up late January, CBLI climbed $0.98 (91.59%).
CBLI stock price history
CBLI IPO was on July 25th, 2006 at $110.80 per share1. Since then, CBLI stock sliced a -98.10%, with a yearly average of -7.50%.
1: Adjusted price after possible price splits or reverse-splits.
CBLI stock historical price chart
CBLI stock reached 52-week highs on February at $5.00, and all-time highs 2007-02-21 with a price of 279.8.
CBLI stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' CBLI stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not detected any price forecast for Cleveland BioLabs stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, when Cleveland BioLabs published its last earnings report, it . As soon as we get its posted EPS from the earnings report, we will update this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a frightening decrease of -41.58% to $1.14 million dollars. Improving that, its profit margin (compared to revenues) boosted to -317.34%, that is $-3.61 million.
|2013||$8.49 M||-||$-17.26 M-203.3%||-|
|2014||$3.70 M||-56.40%||$1.63 M44.0%||-109.44%|
|2015||$2.71 M||-26.84%||$-12.64 M-466.6%||-875.74%|
|2016||$3.52 M||29.92%||$-2.66 M-75.6%||-78.96%|
|2017||$1.95 M||-44.62%||$-9.71 M-498.2%||265.06%|
|2018||$1.14 M||-41.58%||$-3.61 M-317.3%||-62.79%|
Quarterly financial resultsCleveland BioLabs reported $0.24 million in sales for 2018-Q4, a -16.80% less compared to previous quarter. Reported quarter earnings marked $-0.43 M with a profit margin of -183.22%. Profit margin skyrocketed a 206.61% compared to previous quarter when profit margin was -389.84%. When comparing turnover to same quarter last year, Cleveland BioLabs sales marked a spooky drop down and plunged a -72.92%. Looking back to recent quarterly results, Cleveland BioLabs posted 2 negative quarters in a row.
|2017-Q1||$0.57 M||-||$-1.66 M-288.7%||-|
|2017-Q2||$0.21 M||-64.15%||$-5.61 M-2721.2%||237.95%|
|2017-Q3||$0.30 M||44.01%||$-1.26 M-424.7%||-77.52%|
|2017-Q4||$0.87 M||193.16%||$-1.17 M-134.3%||-7.28%|
|2018-Q1||$0.23 M||-73.85%||$-1.22 M-538.1%||4.75%|
|2018-Q2||$0.39 M||72.07%||$-0.85 M-217.3%||-30.51%|
|2018-Q3||$0.28 M||-27.65%||$-1.10 M-389.8%||29.78%|
|2018-Q4||$0.24 M||-16.80%||$-0.43 M-183.2%||-60.90%|
Cleveland BioLabs ownershipReviewing Cleveland BioLabs ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Cleveland BioLabs, 64.39% of all outstanding shares are owned by its staff.
In case of Cleveland BioLabs stock, 3.68% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CBLI stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Cleveland BioLabs:
|Market cap||$23.4 M|
|Total shares||11.4 M|
|Float shares||4.1 M|
|- Institutional holdings (%)||3.7%|
|- Insider holdings (%)||64.4%|
|Shares in short selling||0.0%|
|Tuesday, May 26th, 2020|
|Day range||$2.04 - $2.22|
|Average true range||$0.23|
|50d mov avg||$1.78|
|100d mov avg||$1.94|
|200d mov avg||$1.44|
Cleveland BioLabs performanceTo better understand Cleveland BioLabs performance you must becnhmark its gains with other related stocks in same sector or industry. In the following table, we compare Cleveland BioLabs performance to :